Aztreonam (30 mg/kg of body weight) was administered intravenously over 3 min every 12 h to 30 preterm neonates divided into two groups according to gestational age (mean age for group A was <30 weeks and mean age for group B was >30 weeks) and birth weight (mean weight for group A was <1,500 g and mean weight for group B was >1,500 g). Blood and urine samples were analyzed by microbiological assay. The pharmacokinetics were described by one-compartment and noncompartment models. The mean half-life and clearance for premature infants weighing less than 1,500 g were 5.33 ± 3.61 h and 1.52 1.33 ml/min/kg, respectively; for those weighing more than 1,500 g, the values were 4. 
damage) did not show significant differences in our group of premature infants compared with that in a control group. The dose of 30 mg/kg and a dosage interval of 8 to 12 h could be recommended for the treatment of suitable bacterial infections in all premature infants.
Aztreonam is a monobactam compound that shows excellent activity against aerobic gram-negative bacilli, including Pseudomonas aeruginosa (10) .
Preterm infants, being of low birth weight and often requiring prolonged positive-pressure ventilation and parenteral nutrition, are highly susceptible to infections. Because potentially serious infections require urgent treatment before bacteriological test results are available, babies treated in the first 48 h of life often receive antibiotics when the risk of infection exists but before clinical signs develop, such as following prolonged rupture of the membranes. In this situation, antibiotics must be effective against the whole spectrum of pathogens (6) . Combined with ampicillin, aztreonam could be an ideal antimicrobial agent for initial empiric therapy of sepsis neonatorum, because of its aminoglycosidelike antibacterial activity and the lack of the ototoxicity and nephrotoxicity that occasionally occur in aminoglycoside-treated neonates (2). Here we report and correlate plasma aztreonam concentrations with its pharmacokinetic profile and renal tolerance in low-birth-weight premature infants with suspected serious infections within the first 48 h after birth.
MATERIALS AND METHODS
Study patients. Our study population comprised 30 premature infants hospitalized in the Neonatal Intensive Care Unit, Department of Paediatrics, Verona University, with suspected or proven bacterial infections. After informed, written consent was obtained from the parents, aztreonam was given with ampicillin (100 mg/kg of body weight per day); if bacteriology was positive or infection was clinically present although not confirmed, the premature infants re-* Corresponding author. ceived a full course of antibiotic (mean duration of treatment, 7 days). Routine laboratory tests, hematology, biochemistry, and urinalysis were carried out during treatment to assess the systemic tolerance of the drug.
Drug administration and sampling for drug assay. Aztreonam was given in intravenous doses of 30 mg/kg over 3 min every 12 h. Blood samples were collected at the following times after the first dose of aztreonam, which was given alone: 1, 2, 3, 4.5, 6, and 8 h (no more than four specimens were collected from each premature infant). Urine samples were collected during the first 6 h of therapy and analyzed for the recovery of aztreonam in urine. Additional urine samples were obtained after 1, 3, 4, 7, and 11 days from the beginning of therapy for N-acetyl-P-D-glucosaminidase (NAG) detection.
Aztreonam assay. Concentrations of aztreonam in plasma and urine were measured by an agar disk diffusion technique, with an ampicillin-resistant Escherichia coli strain used as the test organism (5). Urine samples were diluted 1:10 with a 1% phosphate buffer (pH 6). The coefficient of variation for aztreonam was 5%.
NAG enzymuria (a specific and sensitive test for the detection of drug-induced renal tubule damage) was assayed by a colorimetric test by a standard procedure described in a previous study (3) Urinary excretion of NAG in our groups compared with that in a control group is shown in Table 1 . There were no statistically significant differences among the three groups.
Pharmacokinetic profile. The aztreonam kinetic parameters are given in Table 2 . Pharmacokinetic values did not show significant differences among the two groups, even if the t1/2 and CL values in plasma were somewhat different: 5.33 h and 1.52 ml/min/kg, respectively, for group A and 4.08 h and 2.41 ml/min/kg, respectively, for group B.
Safety and tolerance. The intravenous infusion of aztreonam was well tolerated, without any apparent clinical or laboratory adverse effects.
DISCUSSION
In this study, the mean plasma t1/2 ranged from 4.08 to 5.33 h and the systemic CL ranged from 1.52 to 2.41 ml/min/kg. These values are not comparable to those observed previously in low-birth-weight infants (2) . The average volume of distribution observed in the present study was high, corresponding to the high extracellular water content in premature infants. Moreover, the slow renal elimination of the 
